Previous close | 2.5000 |
Open | 2.5000 |
Bid | 1.0000 |
Ask | 4.1000 |
Strike | 20.00 |
Expiry date | 2024-11-15 |
Day's range | 2.5000 - 2.5000 |
Contract range | N/A |
Volume | |
Open interest | 73 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
BEDFORD, Mass., June 03, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.